Pramodini Medica

Why is Pramodini Medicare Ltd falling/rising?

As of N/A, the stock price of Pramodini Medicare Ltd is currently rising at 117.10, but it has declined 4.53% over the past week and 7.94% year-to-date, indicating underperformance relative to the market. The recent price increase may be due to short-term market movements despite ongoing challenges for the company.

As of N/A, the stock price of Pramodini Medicare Ltd is rising, currently at 117.10, with a change of 0.6 (0.52%) upwards. Despite this increase, the stock has experienced a decline of 4.53% over the past week, which contrasts with a smaller decline of 1.15% in the benchmark Sensex during the same period. This indicates that while the stock is currently rising, it has been underperforming relative to the broader market recently. Additionally, year-to-date performance shows a significant decline of 7.94%, suggesting ongoing challenges for the company. However, the immediate rise in price today could be attributed to short-term market movements or investor sentiment, even as the longer-term trends indicate a struggle against broader market conditions.

Which are the latest news on Pramodini Medica?

What does Pramodini Medica do?

Pramodini Medicare Ltd is a micro-cap company in the healthcare services industry, with no available financial data on net sales or profit. Key metrics include a P/E ratio of 15.00 and a debt-equity ratio of 0.00.

Overview:<BR>Pramodini Medicare Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>There are no available details regarding the incorporation year, status changes, or the latest quarter for which sales and profit are reported.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 15.00<BR>Industry P/E: N/A<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.00<BR>Return on Equity: 0.00%<BR>Price-to-Book: 0.00<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the peers of the Pramodini Medica?

Pramodini Medica's peers include Nureca, QMS Medical, Take, Bilcare, Prevest Denpro, Hemant Surgical, Star Imaging, and Jeevan Scienti. QMS Medical leads with a 1-year return of 76.94%, while Prevest Denpro and Star Imaging show excellent management and capital structure ratings.

Peers: The peers of Pramodini Medica are Nureca, QMS Medical, Take, Bilcare, Prevest Denpro, Hemant Surgical, Star Imaging, and Jeevan Scienti.<BR><BR>Quality Snapshot: Excellent management risk is observed at Prevest Denpro and Star Imaging, while Average management risk is found at QMS Medical and Hemant Surgical. Below Average management risk is noted at Nureca, Take, Bilcare, and Jeevan Scienti. Growth is rated as Good for Bilcare and Hemant Surgical, while Average growth is seen at QMS Medical and the rest have Below Average growth. Capital Structure is rated as Excellent for Prevest Denpro and Star Imaging, Good for Nureca and Hemant Surgical, Average for QMS Medical, and Below Average for Take, Bilcare, and Jeevan Scienti.<BR><BR>Return Snapshot: QMS Medical has the highest 1-year return at 76.94%, while Prevest Denpro, Hemant Surgical, Star Imaging, and Jeevan Scienti have a 1-year return of 0.00%, indicating that Pramodini Medica's 1-year return is not available for comparison. Additionally, Take has a negative six-month return of -61.76%.

How big is Pramodini Medica?

As of 31st March, Pramodini Medicare Ltd does not have a specified market capitalization value, and there is no valid financial data for net sales or net profit for the latest four quarters. The balance sheet shows Shareholder's Funds of 53.15 Cr and Total Assets of 91.65 Cr.

As of 31st March, <BR><BR>Market Cap: Pramodini Medicare Ltd does not have a specified market capitalization value available, therefore it cannot be categorized into a market cap type.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for net sales or net profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2026, with Shareholder's Funds amounting to 53.15 Cr and Total Assets totaling 91.65 Cr.